Antiviral effect of entecavir in patients with severe chronic hepatitis B

Objective To study the antiviral effect of entecavir in patients with severe chronic hepatitis B.Methods Eighty patients with no prior history of antiviral therapy were divided randomly into two groups:entecavir group(40 cases),and control group(40 cases).The dosage in the entecavir group was 0.5 mg/d ,and the treatment duration was 48 weeks.The effects of entecavir group and control group on ALT,AST,TBiL,ALB,PTA,e antigen seroconversion rates,HBV DNA were observed during the treatment.Results After 12 weeks treatment,the levels of ALT,AST,TBiL,ALB,PTA,e antigen seroconversion rate and HBV DNA for subjects in entecavir group were 54.06,67.52,39.63,35.45,62.08,24.34 and 6.43,while those for subjects in control group were 76.86,95.67,89.02,31.56,42.89,32.24 and 21.12,resprctively,with significant differences between the two groups. After 24 weeks treatment,the levels of ALT,AST,TBiL,ALB,PTA,e antigen seroconversion rate and HBV DNA for subjects in entecavir group were 50.06,65.02,38.97,36.45,65.08,4.67 and 2.40,while those for subjects in control group were 70.86,80.52,67.02,33.06,45.76,30.78 and 10.12,resprctively,with significant differences between the two groups. The mortality rate in entecavir group and control group were 2.5% and 22.5%.After 48 weeks treatment,the levels of ALT,AST,TBiL,ALB,PTA,e antigen seroconversion rates and HBV DNA for subjects in entecavir group were 40.58,54.23,38.07,38.43,70.18,3.57 and 0,while those for subjects in control group were 56.67,75.52,69.09,33.98,59.86,24.86 and 14.12,resprctively,with significant differences between the two groups. The mortality rate in entecavir group and control group were 5% and 32.5%.Conclusion Entecavir is safe and effective in the treatment of severe chronic hepatitis B.